Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa

This publication has 43 references indexed in Scilit:

• Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism
  Annual Review of Medicine, 2011
• Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban
  The Journal of Bone and Joint Surgery. British volume, 2011
• Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
  New England Journal of Medicine, 2010
• The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor
  Nature Reviews Drug Discovery, 2010
• Newly Identified Events in the RE-LY Trial
  New England Journal of Medicine, 2010
• Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada
  Thrombosis and Haemostasis, 2010
• The Epidemiology of Venous Thromboembolism in the Community
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2008
• Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial
  The Lancet, 2003
• Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement
  New England Journal of Medicine, 2003
• Risks of Anticoagulant Therapy in Pregnant Women with Artificial Heart Valves
  New England Journal of Medicine, 1986